Equities

Brainsway Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Brainsway Ltd

Actions
Health CareMedical Equipment and Services
  • Price (ILa)3,735.00
  • Today's Change60.00 / 1.63%
  • Shares traded61.09k
  • 1 Year change+86.56%
  • Beta1.4425
Data delayed at least 20 minutes, as of Feb 17 2026 15:27 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.

  • Revenue in ILS (TTM)151.39m
  • Net income in ILS19.27m
  • Incorporated2006
  • Employees120.00
  • Location
    Brainsway Ltd16 Hartum Street Rad Tower14Th Floor, Har HaHotzvimJERUSALEM 9777516IsraelISR
  • Phone+972 25813140
  • Fax+972 25812517
  • Websitehttps://www.brainsway.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ilex Medical Ltd906.61m50.36m650.81m176.0012.940.9666.480.71794.503.8980.9160.220.91684.063.705,151,216.005.0912.096.9617.2422.9229.665.5511.172.08--0.067832.690.45017.74-17.69-5.381.29--
Sofwave Medical Ltd237.60m2.11m1.30bn126.001,075.2114.83167.145.470.03350.03356.382.431.783.548.121,885,719.001.58--2.53--75.56--0.8877--2.082.010.0463--18.56--45.08------
Brainsway Ltd151.39m19.27m1.44bn120.0079.606.4657.399.520.46160.46163.485.680.53033.0411.351,261,552.006.75-8.728.53-10.2274.9275.2612.73-17.453.02--0.0879--29.0412.17169.60--2.76--
Vicenne337.47m43.22m1.55bn--35.846.5031.004.5912.4512.4597.1668.63----------------40.66--12.81--1.9271.140.2609--19.57--55.53------
Data as of Feb 17 2026. Currency figures normalised to Brainsway Ltd's reporting currency: Israeli Shekel ILS

Institutional shareholders

6.72%Per cent of shares held by top holders
HolderShares% Held
Psagot Mutual Funds Ltd.as of 30 Nov 2025829.07k2.12%
Harel Mutual Funds Ltd.as of 30 Nov 2025464.12k1.19%
Meitav Mutual Funds Ltd.as of 30 Nov 2025463.87k1.18%
Ayalon Mutual Funds Ltd.as of 30 Nov 2025276.82k0.71%
Sigma Mutual Funds Ltd.as of 30 Nov 2025184.70k0.47%
KSM Mutual Funds Ltd.as of 30 Nov 2025102.45k0.26%
Excellence Nessuah Mutual Funds Management Ltd.as of 30 Sep 2024101.56k0.26%
Analyst IMS Mutual Funds Management (1986) Ltd.as of 30 Nov 202584.81k0.22%
Lamashkia Mutual Funds Management Co. (1982) Ltd.as of 30 Nov 202573.51k0.19%
Bessemer Investment Management LLCas of 31 Oct 202550.63k0.13%
More ▼
Data from 30 Nov 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.